A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetic Profiles of Y-3 in Healthy Adult Volunteers in the United States
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs Y 3 (Primary)
- Indications Stroke
- Focus Pharmacokinetics
- Sponsors NeuroDawn
- 20 Jan 2025 New trial record